Program

Check back for updates on the 2019 Genitourinary Cancers Symposium program.

The 2019 Genitourinary Cancers Symposium will feature an array of multidisciplinary sessions covering prostate, renal, urothelial, penile, testicular, and adrenal cancers. World-renowned faculty will present on the most clinically relevant topics across these disease sites with an emphasis on multimodality therapy and value in cancer care.

6:30 AM-7:55 AM Complimentary Continental Breakfast
6:30 AM-6:15 PM Exhibits Open
7:00 AM-7:50 AM Rapid Abstract Session B: Urothelial Carcinoma and Penile, Urethral, Testicular, and Adrenal Cancers

Jeffrey Holzbeierlein, MD, FACS—Chair
University of Kansas Health System

Thomas J. Pugh, MD—Chair
University of Colorado, Denver

Abstract 409: Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).
First Author: Andrea Necchi, MD

Question and Answer

Abstract 355: Gemcitabine-carboplatin (GCb) versus gemcitabine-oxaliplatin (GemOx) in cisplatin un-fit advanced urothelial carcinoma: Randomized phase II study (COACH Study).
First Author: Jae-Lyun Lee, MD

Question and Answer

Abstract 356: Long-term outcomes of hypoxia modification in bladder preservation: Update from BCON trial.
First Author: Yee Pei Song, FRCR, MBBCh, MRCP

Question and Answer

Abstract 509: Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).
First Author: Jean-Michel Lavoie, MD

Question and Answer

Abstract 510: Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.
First Author: Stefanie Christine Fischer, MD

Question and Answer
7:55 AM-9:25 AM

Welcome and General Session 4: Challenges and Advances in Perioperative and Local Therapy for Urothelial Carcinoma

Jeanny B. Aragon-Ching, MD, FACP—Chair
Inova Schar Cancer Institute

Jean H. Hoffman-Censits, MD—Chair
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 

Paul L. Nguyen, MD
Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School
Welcome

Yair Lotan, MD
The University of Texas Southwestern Medical Center
Genomic Insights and Biomarkers for Treatment Selection in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer

Andrea Necchi, MD
Fondazione IRCCS Istituto Nazionale dei Tumori
Perioperative Immunotherapy in Urothelial Carcinoma: State of Existing Evidence

Surena F. Matin, MD, FACS
The University of Texas MD Anderson Cancer Center
Challenges of Therapy in Upper-Tract Urothelial Carcinoma

Debate: The Optimal Local Treatment for Muscle-Invasive Bladder Cancer

Jeanny B. Aragon-Ching, MD, FACP
Inova Schar Cancer Institute
Case Presentation

Michael Cookson, MD
University of Oklahoma Health Sciences Center
Radical Cystectomy Is the Best Option for Muscle-Invasive Bladder Cancer

Jason A. Efstathiou, MD, DPhil
Massachusetts General Hospital
Trimodality Therapy Is the Best Option for Muscle-Invasive Bladder Cancer


Abstract 350: Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).
First Author: Arjun Vasant Balar, MD

Panel Question and Answer

9:30 AM-10:15 AM Keynote Lecture

James L. Gulley, MD, PhD, FACP
The National Cancer Institute at the National Institutes of Health
Immunotherapy Across Genitourinary Malignancies

Panel Question and Answer
10:15 AM-10:45 AM Break
10:45 AM-12:15 PM General Session 5: Multimodality Treatment in Challenging Cases of Urothelial Carcinoma

Ananya Choudhury, MA, PhD, MRCP, FRCR—Chair
The Christie NHS Foundation Trust and University of Manchester

Brant Inman, MD—Chair
Duke University Medical Center

Case Panel Discussion

Robert A. Huddart, MBBS, MRCP, FRCR, PhD
The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust
Radiation Oncologist

Matt D. Galsky, MD, FASCO
Icahn School of Medicine at Mount Sinai
Medical Oncologist

Eila C. Skinner, MD
Stanford University
Urologist

Giovanni Barchetti, MD
Sapienza University of Rome
Radiologist

Abstract 351: Randomized phase III trial of adjuvant sequential chemotherapy plus radiotherapy versus adjuvant radiotherapy alone for locally advanced bladder cancer after radical cystectomy: Urothelial carcinoma subgroup analysis.
First Author: Mohamed S. Zaghloul, MD

Panel Question and Answer
12:15 PM-1:45 PM Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
With Complimentary Boxed Lunch
12:15 PM-1:45 PM Trials in Progress Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
With Complimentary Boxed Lunch
12:30 PM-1:30 PM

Breakout Session: Controversies in Data Interpretation

 

Jennifer Rider, ScD, MPH—Chair
Boston University School of Public Health

 

Point-Counterpoint: Subgroup Analyses Can be Used to Change Clinical Practice Guidelines

 

Jennifer Rider, ScD, MPH
Boston University School of Public Health
Moderator

 

Ludovic Trinquart, PhD
Boston University School of Public Health
Biostatistician

 

Atish Choudhury, MD, PhD
Dana-Farber Cancer Institute
Medical Oncologist

 

Ana Aparicio, MD
The University of Texas MD Anderson Cancer Center
Medical Oncologist

 

Panel Question and Answer

 

Steven Goodman, MD, PhD, MHS
Stanford School of Medicine
The P-Value Debate: Lower Them or Leave Them?

 

Panel Question and Answer

 
1:45 PM-3:15 PM Oral Abstract Session B: Urothelial Carcinoma and Penile, Urethral, Testicular, and Adrenal Cancers
Jeanny B. Aragon-Ching, MD, FACP—Chair

Inova Schar Cancer Institute

Claud Grigg, MD—Chair
Levine Cancer Institute

Abstract 354: Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
First Author: Scott T. Tagawa, MD, MS

Abstract 353: Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts).
First Author: Ronald De Wit, MD, PhD

Matthew I. Milowsky, MD
The University of North Carolina at Chapel Hill
Discussion

Abstract 507: The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.
First Author: Peter Albers, MD

Abstract 508: Malignant pheochromocytoma: A comprehensive genomic profiling study.
First Author: Gennady Bratslavsky, MD

Siamak Daneshmand, MD
University of Southern California Norris Comprehensive Cancer Center
Discussion

Panel Question and Answer
3:15 PM-3:45 PM Break
3:45 PM-5:15 PM General Session 6: Improving Outcomes in Rare Genitourinary Malignancies

Christian K. Kollmannsberger, MD—Chair
BC Cancer - Vancouver Cancer Centre

N. Reed Dunnick, MD—Chair
University of Michigan

Craig R. Nichols, MD, FACP, FASCO
Testicular Cancer Commons and SWOG Group Chair's Office
Practice Makes Perfect: Should All Testicular Cancer Cases Be Discussed With High-Volume Centers?

Robert J. Hamilton, MD, MPH
Princess Margaret Cancer Centre, University Health Network
MicroRNA 371 As a Biomarker: Is It a Breakthrough?

Penile Carcinoma Regional Lymph Node Involvement: Radiation Versus Surgery

Karen E. Hoffman, MD, MPH
The University of Texas MD Anderson Cancer Center
Radiation Oncologist

Nicola Nicolai, MD
Fondazione IRCCS Istituto Nazionale dei Tumori
Surgeon


Abstract 505: Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors.
First Author: Jad Chahoud, MD

Abstract 506: Comprehensive analysis of metastatic seminoma germ cell tumors shows divergent expression of immune-related pathways.
First Author: Tim Nestler, MD

Panel Question and Answer
5:15 PM-6:15 PM Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Reception With Complimentary Wine and Cheese
5:15 PM-6:15 PM Trials in Progress Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Reception With Complimentary Wine and Cheese
5:30 PM- 6:15 PM Poster Walks

Peter E. Clark, MD—Poster Walk Leader

Levine Cancer Institute, Atrium Health

Ananya Choudhury, MA, PhD, MRCP, FRCR—Poster Walk Leader
The Christie NHS Foundation Trust and University of Manchester